Design Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Design Therapeutics's earnings have been declining at an average annual rate of -37.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 160.5% per year.
Belangrijke informatie
-37.2%
Groei van de winst
-19.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -160.5% |
| Rendement op eigen vermogen | -19.3% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10Opbrengsten en kosten
Hoe Design Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -51 | 19 | -13 |
| 31 Mar 24 | 0 | -59 | 20 | 0 |
| 31 Dec 23 | 0 | -67 | 21 | 0 |
| 30 Sep 23 | 0 | -72 | 22 | 30 |
| 30 Jun 23 | 0 | -74 | 21 | 30 |
| 31 Mar 23 | 0 | -69 | 20 | 0 |
| 31 Dec 22 | 0 | -63 | 19 | 0 |
| 30 Sep 22 | 0 | -57 | 18 | 0 |
| 30 Jun 22 | 0 | -51 | 16 | 0 |
| 31 Mar 22 | 0 | -43 | 14 | 0 |
| 31 Dec 21 | 0 | -36 | 11 | 0 |
| 30 Sep 21 | 0 | -28 | 8 | 0 |
| 30 Jun 21 | 0 | -19 | 6 | 0 |
| 31 Mar 21 | 0 | -13 | 4 | 0 |
| 31 Dec 20 | 0 | -8 | 2 | 0 |
| 31 Dec 19 | 1 | -2 | 1 | 0 |
Kwaliteitswinsten: DSGN is currently unprofitable.
Groeiende winstmarge: DSGN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DSGN is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Versnelling van de groei: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: DSGN has a negative Return on Equity (-19.34%), as it is currently unprofitable.